FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702915> ?p ?o ?g. }

• W4385702915 endingPage "104089" @default.
• W4385702915 startingPage "104089" @default.
• W4385702915 abstract "Up to 20% of breast cancer overexpress HER2 protein, making it a reliable target for antibody-based treatments. In early HER2-positive breast cancer avoiding anthracycline-based chemotherapy is a challenge. Based on the single-arm phase II APT trial results, adjuvant paclitaxel/trastuzumab is an accepted regimen for patients with stage I HER2-positive disease. In our retrospective study of 240 patients, the median tumor size was 12.0 mm (IQR 9 -15), and 204 (85%) had estrogen receptor-positive disease. After a median follow-up of 4.6 years, 3-year real-world disease-free survival, distant DFS, and overall survival were 98.8% (95% confidence interval (CI), 96.2-99.6), 99.2% (95% CI, 96.7-99.8), and 98.3% (95% CI, 96.2-99.6), respectively. In a real-world setting, an adjuvant paclitaxel/trastuzumab regimen was associated with low recurrence rates among women with stage I, HER2-positive breast cancer. Additionally, we reviewed other treatment optimization strategies attempted or ongoing in HER2-positive breast cancer." @default.
• W4385702915 created "2023-08-10" @default.
• W4385702915 creator A5014689698 @default.
• W4385702915 creator A5025723323 @default.
• W4385702915 creator A5031325232 @default.
• W4385702915 creator A5034961078 @default.
• W4385702915 creator A5034980760 @default.
• W4385702915 creator A5036201601 @default.
• W4385702915 creator A5038676900 @default.
• W4385702915 creator A5044131985 @default.
• W4385702915 creator A5052697647 @default.
• W4385702915 creator A5057557133 @default.
• W4385702915 creator A5068291706 @default.
• W4385702915 creator A5071060598 @default.
• W4385702915 creator A5072581506 @default.
• W4385702915 creator A5072599112 @default.
• W4385702915 creator A5080255285 @default.
• W4385702915 creator A5082045927 @default.
• W4385702915 creator A5082230442 @default.
• W4385702915 creator A5082293621 @default.
• W4385702915 creator A5087380706 @default.
• W4385702915 date "2023-10-01" @default.
• W4385702915 modified "2023-09-26" @default.
• W4385702915 title "Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab" @default.
• W4385702915 cites W2006070721 @default.
• W4385702915 cites W2090855460 @default.
• W4385702915 cites W2095633632 @default.
• W4385702915 cites W2113450161 @default.
• W4385702915 cites W2144124503 @default.
• W4385702915 cites W2146384083 @default.
• W4385702915 cites W2149908785 @default.
• W4385702915 cites W2902218997 @default.
• W4385702915 cites W2911681680 @default.
• W4385702915 cites W2928807055 @default.
• W4385702915 cites W3003670850 @default.
• W4385702915 cites W3037385414 @default.
• W4385702915 cites W3081892489 @default.
• W4385702915 cites W3092280067 @default.
• W4385702915 cites W3160666703 @default.
• W4385702915 cites W3161369373 @default.
• W4385702915 cites W3165177412 @default.
• W4385702915 cites W3179495039 @default.
• W4385702915 cites W3204042287 @default.
• W4385702915 cites W3213317935 @default.
• W4385702915 cites W4211123279 @default.
• W4385702915 cites W4254815115 @default.
• W4385702915 cites W4281640394 @default.
• W4385702915 cites W4281647759 @default.
• W4385702915 cites W4294308288 @default.
• W4385702915 cites W4322490942 @default.
• W4385702915 cites W4322775112 @default.
• W4385702915 cites W4322775408 @default.
• W4385702915 doi "https://doi.org/10.1016/j.critrevonc.2023.104089" @default.
• W4385702915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37562696" @default.
• W4385702915 hasPublicationYear "2023" @default.
• W4385702915 type Work @default.
• W4385702915 citedByCount "0" @default.
• W4385702915 crossrefType "journal-article" @default.
• W4385702915 hasAuthorship W4385702915A5014689698 @default.
• W4385702915 hasAuthorship W4385702915A5025723323 @default.
• W4385702915 hasAuthorship W4385702915A5031325232 @default.
• W4385702915 hasAuthorship W4385702915A5034961078 @default.
• W4385702915 hasAuthorship W4385702915A5034980760 @default.
• W4385702915 hasAuthorship W4385702915A5036201601 @default.
• W4385702915 hasAuthorship W4385702915A5038676900 @default.
• W4385702915 hasAuthorship W4385702915A5044131985 @default.
• W4385702915 hasAuthorship W4385702915A5052697647 @default.
• W4385702915 hasAuthorship W4385702915A5057557133 @default.
• W4385702915 hasAuthorship W4385702915A5068291706 @default.
• W4385702915 hasAuthorship W4385702915A5071060598 @default.
• W4385702915 hasAuthorship W4385702915A5072581506 @default.
• W4385702915 hasAuthorship W4385702915A5072599112 @default.
• W4385702915 hasAuthorship W4385702915A5080255285 @default.
• W4385702915 hasAuthorship W4385702915A5082045927 @default.
• W4385702915 hasAuthorship W4385702915A5082230442 @default.
• W4385702915 hasAuthorship W4385702915A5082293621 @default.
• W4385702915 hasAuthorship W4385702915A5087380706 @default.
• W4385702915 hasConcept C121608353 @default.
• W4385702915 hasConcept C126322002 @default.
• W4385702915 hasConcept C143998085 @default.
• W4385702915 hasConcept C146357865 @default.
• W4385702915 hasConcept C151730666 @default.
• W4385702915 hasConcept C2776694085 @default.
• W4385702915 hasConcept C2776802502 @default.
• W4385702915 hasConcept C2777292972 @default.
• W4385702915 hasConcept C2777511904 @default.
• W4385702915 hasConcept C2777863537 @default.
• W4385702915 hasConcept C2777982462 @default.
• W4385702915 hasConcept C2779786085 @default.
• W4385702915 hasConcept C2781413609 @default.
• W4385702915 hasConcept C44249647 @default.
• W4385702915 hasConcept C530470458 @default.
• W4385702915 hasConcept C71924100 @default.
• W4385702915 hasConcept C86803240 @default.
• W4385702915 hasConceptScore W4385702915C121608353 @default.
• W4385702915 hasConceptScore W4385702915C126322002 @default.
• W4385702915 hasConceptScore W4385702915C143998085 @default.
• W4385702915 hasConceptScore W4385702915C146357865 @default.

• next